Strategic partnerships Amphista is backed by high-profile investors including Advent Life Sciences, Forbion, Gilde Healthcare, Novartis Venture Fund, SV's Dementia Discovery Fund and Eli Lilly, signaling strong funding credibility and potential co-development or licensing discussions with pharma partners.

Innovative platform The company leverages a proprietary Eclipsys platform to develop bifunctional Targeted Glue therapeutics, offering differentiated mechanisms that may appeal to collaborators seeking novel degradation modalities beyond traditional TPD approaches.

Strategic leadership New leadership team including CEO Louise Modis and CMO Patrick Kelly, as well as imminent IND filing for AMX-883, indicate a shift toward late-stage readiness and opportunities for strategic collaborations around clinical programs.

Focus on high-need targets Recent programs target SMARCA2 degraders for SMARCA4-mutant NSCLC and BRD9, addressing difficult cancer targets with significant unmet need, presenting co-development or licensing potential for oncology-focused partners.

Global visibility Active participation in major conferences (AACR 2026) and press on new preclinical data enhances visibility for potential licensees and research collaborations, creating openings for outreach to interested biotechs and pharma companies.